Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Core Insights - Nexalin Technology, Inc. has received Institutional Review Board (IRB) approval for a clinical trial at the University of California, San Diego (UCSD) to evaluate its HALO™ Clarity devices for treating mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military and civilian populations [1][2] Company Overview - Nexalin Technology specializes in developing innovative neurostimulation products aimed at addressing the global mental health crisis, utilizing non-invasive bioelectronic medical technology [4] - The company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology offers a drug-free alternative for neurological and mental health conditions, minimizing side effects associated with traditional treatments [6] Clinical Trial Details - The initial shipment of HALO™ Clarity devices has been delivered to UCSD, with patient recruitment for the study commencing immediately [1][3] - An additional 40-50 HALO devices will be supplied as the study progresses, which will be integrated with Nexalin's app-controlled remote monitoring system for real-time tracking of patient progress [3][6] Technology and Advantages - The HALO™ Clarity device is designed for non-invasive deep-brain stimulation, providing a patient-centered treatment experience [3] - The combination of DIFS technology with an advanced virtual clinic model allows for seamless oversight of treatment adherence and progress [3][6] Future Aspirations - The initiation of patient recruitment is viewed as a significant milestone in validating the HALO Clarity device for TBI and PTSD treatment, with the potential to make non-invasive deep brain stimulation a viable solution for affected individuals [3]